Suppr超能文献

治疗和预防肝性脑病的微生物学方法

Microbial Approaches to Treat and Prevent Hepatic Encephalopathy.

作者信息

Munk Lauridsen Mette, Jonasson Elise, Bajaj Jasmohan S

机构信息

Department for Regional Health Research, University Hospital of Southern Denmark, Finsensgade 35 6700, Esbjerg, Denmark.

Department of Medicine, Virginia Commonwealth University, Richmond, VA, USA.

出版信息

Gastroenterol Clin North Am. 2025 Jun;54(2):429-451. doi: 10.1016/j.gtc.2024.12.006. Epub 2025 Jan 23.

Abstract

This review articulates the significance of the gut-liver-brain axis in understanding hepatic encephalopathy (HE), emphasizing the role of gut microbiota in influencing liver and brain health. Key treatments like lactulose, rifaximin, probiotics, and fecal microbiota transplantation are examined for their ability to modulate the gut microbiome, thereby mitigating HE symptoms through reduced neurotoxin production and enhanced gut barrier integrity. The synopsis highlights both established and emerging microbial therapies, presenting them as crucial to the management and future strategies of HE. This comprehensive overview explores current therapeutic approaches alongside promising future interventions, suggesting that personalized microbiome-focused treatments may revolutionize HE management.

摘要

本综述阐明了肠-肝-脑轴在理解肝性脑病(HE)中的重要性,强调了肠道微生物群在影响肝脏和大脑健康方面的作用。研究了乳果糖、利福昔明、益生菌和粪便微生物群移植等关键治疗方法调节肠道微生物组的能力,从而通过减少神经毒素产生和增强肠道屏障完整性来减轻HE症状。本综述突出了既定的和新兴的微生物疗法,将它们视为HE管理和未来策略的关键。这一全面概述探讨了当前的治疗方法以及未来有前景的干预措施,表明以微生物组为重点的个性化治疗可能会彻底改变HE的管理方式。

相似文献

1
Microbial Approaches to Treat and Prevent Hepatic Encephalopathy.
Gastroenterol Clin North Am. 2025 Jun;54(2):429-451. doi: 10.1016/j.gtc.2024.12.006. Epub 2025 Jan 23.
2
Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
Curr Opin Gastroenterol. 2019 May;35(3):145-154. doi: 10.1097/MOG.0000000000000527.
3
Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
J Hepatol. 2021 Jan;74(1):80-88. doi: 10.1016/j.jhep.2020.06.046. Epub 2020 Jul 15.
4
The Link between Gut Microbiota and Hepatic Encephalopathy.
Int J Mol Sci. 2022 Aug 12;23(16):8999. doi: 10.3390/ijms23168999.
5
Update on the Therapeutic Management of Hepatic Encephalopathy.
Curr Gastroenterol Rep. 2018 Apr 11;20(5):21. doi: 10.1007/s11894-018-0627-8.
6
Prophylaxis of hepatic encephalopathy: current and future drug targets.
Hepatol Int. 2024 Aug;18(4):1096-1109. doi: 10.1007/s12072-024-10647-9. Epub 2024 Mar 16.
7
Long-term Outcomes of Fecal Microbiota Transplantation in Patients With Cirrhosis.
Gastroenterology. 2019 May;156(6):1921-1923.e3. doi: 10.1053/j.gastro.2019.01.033. Epub 2019 Jan 18.
8
Nonpharmacologic Management of Hepatic Encephalopathy: An Update.
Clin Liver Dis. 2020 May;24(2):243-261. doi: 10.1016/j.cld.2020.01.003. Epub 2020 Feb 26.
9
Nontraditional Treatment of Hepatic Encephalopathy.
Clin Liver Dis. 2024 May;28(2):297-315. doi: 10.1016/j.cld.2024.01.007. Epub 2024 Feb 15.

本文引用的文献

1
Gut microbiome profiles to exclude the diagnosis of hepatic encephalopathy in patients with cirrhosis.
Gut Microbes. 2024 Jan-Dec;16(1):2392880. doi: 10.1080/19490976.2024.2392880. Epub 2024 Aug 27.
3
High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study.
Aliment Pharmacol Ther. 2024 Apr;59(8):973-983. doi: 10.1111/apt.17909. Epub 2024 Feb 22.
4
The RIVET RCT: Rifamycin SV MMX improves muscle mass, physical function, and ammonia in cirrhosis and minimal encephalopathy.
Hepatol Commun. 2024 Feb 3;8(2). doi: 10.1097/HC9.0000000000000384. eCollection 2024 Feb 1.
5
The Multi-dimensional Challenge of Poor Oral Health in Cirrhosis-Disparities and Solutions.
Gastroenterology. 2024 May;166(5):717-722. doi: 10.1053/j.gastro.2024.01.010. Epub 2024 Jan 13.
6
The contributions of bacteria metabolites to the development of hepatic encephalopathy.
Liver Res. 2023 Dec;7(4):296-303. doi: 10.1016/j.livres.2022.11.005. Epub 2022 Nov 15.
8
The Current and Future State of Microbiome Therapeutics in Liver Disease.
Am J Gastroenterol. 2024 Jan 1;119(1S):S36-S41. doi: 10.14309/ajg.0000000000002581.
9
Frailty in end-stage liver disease: Understanding pathophysiology, tools for assessment, and strategies for management.
World J Gastroenterol. 2023 Dec 14;29(46):6028-6048. doi: 10.3748/wjg.v29.i46.6028.
10
Proton Pump Inhibitors Increases Longitudinal Risk of Mortality, Decompensation, and Infection in Cirrhosis: A Meta-Analysis.
Dig Dis Sci. 2024 Jan;69(1):289-297. doi: 10.1007/s10620-023-08150-6. Epub 2023 Nov 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验